Inhibrx Biosciences, Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
At close
$95.40
+$1.77 (+1.89%) Close
Pre-market$93.73
−$1.66 (−1.75%) 7:28 PM ET
Prev closePrevC$93.63
OpenOpen$93.67
Day highHigh$95.40
Day lowLow$93.67
VolumeVol679
Avg volAvgVol602,094
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.37B
P/E ratio
-11.37
FY Revenue
$1.30M
EPS
-8.39
Gross Margin
100.00%
Sector
Healthcare
AI report sections
MIXED
INBX
Inhibrx Biosciences, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
−18% (Below avg)
Vol/Avg: 0.82×
RSI
43.50(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.09 (Strong)
MACD: 0.15 Signal: 0.06
Short-Term
-3.04 (Weak)
MACD: -0.70 Signal: 2.33
Long-Term
-3.00 (Weak)
MACD: 7.76 Signal: 10.76
Intraday trend score
37.00
LOW26.70HIGH52.00
Latest news
INBX•12 articles•Positive: 3Neutral: 2Negative: 0
NeutralBenzinga• Prnewswire
Inhibrx Reports First Quarter 2026 Financial Results
Inhibrx Biosciences reported Q1 2026 results with a net loss of $33.4 million ($2.15 per share), improved from $43.3 million in Q1 2025. The company raised $75 million in debt financing, bringing cash to $161.7 million. R&D expenses decreased to $25.2 million due to lower clinical trial costs. Key programs include INBRX-106 for head and neck cancer with Phase 2 PFS data expected in Q4 2026, and ozekibart (INBRX-109) for colorectal cancer and chondrosarcoma with a BLA submitted to the FDA.
INBXclinical-stage biopharmaceuticalINBRX-106ozekibarthead and neck squamous cell carcinomacolorectal cancerchondrosarcomaPhase 2 trial
Sentiment note
Mixed results: improved net loss year-over-year and successful debt financing provide positive cash runway, but the company remains unprofitable with significant ongoing losses. Clinical progress on two programs is offset by the inherent risks of clinical-stage development and the need for continued capital raises. Stock price down 9.62% suggests market skepticism despite operational improvements.
PositiveBenzinga• Vandana Singh
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
Inhibrx Biosciences is in early-stage discussions with multiple major pharmaceutical companies regarding a potential joint spin-off of its cancer drug INBRX-106 and another oncology asset, with combined valuations potentially exceeding $9 billion. INBRX-106 is being tested as a standalone therapy and in combination with Merck's Keytruda. The stock surged 39.86% to $116.76 on the news.
INBXMRKLLYAZNcancer therapyINBRX-106M&Abiotech
Sentiment note
Stock surged 39.86% on news of acquisition interest from major drugmakers with valuations exceeding $8 billion for its cancer drug portfolio. Early-stage discussions with multiple pharma companies indicate strong market interest in its assets.
PositiveBenzinga• Piero Cingari
Stocks Soar To Records After Weak Inflation, Ford Jumps 10%: What's Moving Markets Friday?
U.S. stock markets hit record highs after September's inflation data showed a softer-than-expected 3% annual rate, boosting investor confidence in potential Federal Reserve interest rate cuts. Major indices like S&P 500 and Dow Jones reached new peaks, with technology stocks leading the rally.
Stock surged over 90% after announcing encouraging trial results for cancer drug ozekibart.
PositiveBenzinga• Mohd Haider
Why Are Inhibrx Biosciences Shares Soaring 76% After Hours?
Inhibrx Biosciences announced positive Phase 2 trial results for ozekibart in treating chondrosarcoma, demonstrating significant progression-free survival improvement and becoming the first experimental therapy to show such benefit in this cancer type.
Stock rose 76% after hours due to successful clinical trial results showing statistically significant progression-free survival improvement in chondrosarcoma treatment, with 52% lower risk of disease progression or death compared to placebo
NeutralInvesting.com• Emilio Ghigini
Inhibrx stock rated 'Market Perform' by JMP after Sanofi acquisition - Investing.com
JMP Securities initiated coverage on Inhibrx Inc. with a Market Perform rating following the acquisition of INBRX-101 by Sanofi. The newly formed Inhibrx Biosciences has a strong financial foundation, but faces challenges with negative profitability metrics.
The Market Perform rating indicates a neutral outlook on the company's stock, as Inhibrx Biosciences embarks on its development journey with a reinforced balance sheet but faces profitability challenges.
UnknownZacks Investment Research• Zacks Equity Research
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -61.68% and 1,534%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
INBXVCEL
UnknownZacks Investment Research• Zacks Equity Research
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of 11.36% and 1.49%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sanofi (SNY) is set to acquire Inhibrx's (INBX) rare disease pipeline candidate, INBRX-101.
SNYJNJIONSINBX
UnknownZacks Investment Research• Zacks Equity Research
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.
SNYGILDEXELINBX
UnknownZacks Investment Research• Zacks Equity Research
Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?
Inhibrx, Inc. (INBX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
INBXCCCC
UnknownZacks Investment Research• Zacks Equity Research
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
SNYNVOCTMXINBX
UnknownMarketWatch• MarketWatch
Here’s what big consumer-sentiment gains mean for the stock market — and this one is unusual
Historically, consumer sentiment doesn't usually pick up while the business outlook is gloomy, except coming out of recessions.
MMMGENFLXTXN
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
